Paion Ag (FRA:PA8) Institutional Ownership : 0.32% (As of Jun. 07, 2024)

View and export this data going back to 2005. Start your Free Trial

What is Paion Ag Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Paion Ag's institutional ownership is 0.32%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Paion Ag's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Paion Ag's Float Percentage Of Total Shares Outstanding is 0.00%.

Paion Ag Institutional Ownership Historical Data

The historical data trend for Paion Ag's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paion Ag Institutional Ownership Chart

Paion Ag Historical Data

The historical data trend for Paion Ag can be seen below:

	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30	2024-05-31
Institutional Ownership	2.23	1.64	0.34	0.32	0.32	0.32	0.32	0.32	0.32	0.32

Paion Ag Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Paion Ag (FRA:PA8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Paion Ag (FRA:PA8) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

PAIOF:USA

Address

Heussstrasse 25, Aachen, DEU, 52078

Website

https://www.paion.com

Paion Ag is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.

Paion Ag (FRA:PA8) Headlines

No Headlines